• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Tattooed Chef Are Trading Lower By 47%; Here Are 20 Stocks Moving Premarket

    7/3/23 8:15:02 AM ET
    $AGRX
    $ALLR
    $ATHX
    $BACK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGRX alert in real time by email

    Gainers

    • Micromobility.com Inc. (NASDAQ:MCOM) shares surged 60% to $0.18 in pre-market trading. micromobility.com recently reported a strategic realignment to strengthen its financial position and drive profitability.
    • Fortress Biotech, Inc. (NASDAQ:FBIO) shares gained 38.2% to $0.76 in pre-market trading. Urica Therapeutics, a Fortress Biotech subsidiary company, recently disclosed topline data from the Phase 1 clinical trial evaluating dotinurad in healthy volunteers in the United States.
    • IMAC Holdings, Inc. (NASDAQ:BACK) shares rose 35.9% to $0.1495 in pre-market trading. Theralink recently signed definitive merger agreement to be acquired by IMAC Holdings.
    • FLJ Group Limited (NASDAQ:FLJ) shares rose 23.9% to $0.3680 in pre-market trading. The company said Mr. Lin Zhou has resigned as an independent director and a member of the audit committee of the Company, effective June 30, 2023.
    • SQZ Biotechnologies Company (NYSE:SQZ) shares gained 20.7% to $0.3260 in pre-market trading after declining 11% on Friday.
    • ENGlobal Corporation (NASDAQ:ENG) gained 16.2% to $0.4380 in pre-market trading. ENGlobal was recently granted 180-day extension by NASDAQ to regain compliance with minimum bid price rule.
    • Athersys, Inc. (NASDAQ:ATHX) rose 14.9% to $1.00 in pre-market trading after gaining around 6% on Friday.
    • Greenbrook TMS Inc. (NASDAQ:GBNH) shares climbed 14.4% to $0.7674 in pre-market trading. Greenbrook TMS recently announced the acceptance of Mr. Benjamin Klein's resignation from the board of directors of the Company.
    • XPeng Inc. (NYSE:XPEV) gained 10.7% to $14.86 in pre-market trading after the company announced a significant increase in vehicle deliveries for June and the second quarter of 2023.
    • Tesla, Inc. (NASDAQ:TSLA) rose 6.2% to $278.09 in pre-market trading after the company reported record deliveries numbers for the second quarter. The company’s quarterly deliveries came in at 466,140 units, compared to the company-compiled estimate of 446,823 units and the FactSet-compiled estimate of 445,000 units.

    Losers

    • Tattooed Chef, Inc. (NASDAQ:TTCF) fell 46.9% to $0.29 in pre-market trading after the company said that it intends to file for voluntary Chapter 11 Bankruptcy protection.
    • Baudax Bio, Inc. (NASDAQ:BXRX) fell 22.2% to $0.91 in pre-market trading. Baudax Bio shares jumped around 125% on Friday after the company agreed to acquire TeraImmune in a stock-for-stock transaction.
    • VBI Vaccines Inc. (NASDAQ:VBIV) fell 12.5% to $2.88 in pre-market. VBI Vaccines shares surged 75% on Friday after the company announced a $25.35 million contract from the Department of Health and Human Services.
    • Agile Therapeutics, Inc. (NASDAQ:AGRX) fell 12.2% to $2.59 in pre-market trading after gaining around 13% on Friday. Agile Therapeutics named Scott Coiante to serve as Senior Vice President, CFO and Treasurer, effective Aug. 16.
    • Bluejay Diagnostics, Inc. (NASDAQ:BJDX) fell 12.1% to $0.2311 in pre-market trading after jumping 30% on Friday.
    • Bright Health Group, Inc. (NASDAQ:BHG) shares dropped 11.4% to $10.83 in pre-market trading. Bright Health shares gained around 12% on Friday after the company agreed to sell its California Medicare advantage business, Brand New Day and Central Health plan to Molina Healthcare for $600 million.
    • TOP Financial Group Limited (NASDAQ:TOP) shares fell 8.7% to $8.57 in pre-market trading. TOP Financial shares gained over 20% on Friday after the company reported FY23 financial results.
    • TC Biopharm (Holdings) Plc (NASDAQ:TCBP) fell 7.5% to $0.5012 in pre-market trading after dropping over 4% on Friday.
    • Motorsport Games Inc. (NASDAQ:MSGM) fell 6.3% to $4.03 in pre-market trading. Motorsport Games recently posted better-than-expected first-quarter results.
    • Allarity Therapeutics, Inc. (NASDAQ:ALLR) shares dropped 6% to $6.21 in pre-market trading. Allarity Therapeutics recently announced a reverse stock split of common stock.

     

    Now Read This: Fear & Greed Index Remains In 'Extreme Greed' Zone After Nasdaq Records Best H1 Since 1983

    Get the next $AGRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGRX
    $ALLR
    $ATHX
    $BACK

    CompanyDatePrice TargetRatingAnalyst
    Tesla Inc.
    $TSLA
    2/12/2026$550.00Buy
    Tigress Financial
    Tesla Inc.
    $TSLA
    1/30/2026$150.00 → $145.00Underweight
    Analyst
    Tesla Inc.
    $TSLA
    1/12/2026$120.00 → $130.00Underweight
    Wells Fargo
    Tesla Inc.
    $TSLA
    1/2/2026$444.00 → $439.00Hold
    Truist
    Tesla Inc.
    $TSLA
    12/8/2025$425.00Overweight → Equal-Weight
    Morgan Stanley
    XPeng Inc.
    $XPEV
    11/18/2025$29.00Neutral → Buy
    Daiwa Securities
    Tesla Inc.
    $TSLA
    10/29/2025$341.00 → $471.00Neutral
    BofA Securities
    Tesla Inc.
    $TSLA
    10/23/2025$450.00 → $485.00Outperform
    Mizuho
    More analyst ratings

    $AGRX
    $ALLR
    $ATHX
    $BACK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Delta John bought $13,020 worth of shares (5,000 units at $2.60), increasing direct ownership by 71% to 12,000 units (SEC Form 4)

    4 - Motorsport Games Inc. (0001821175) (Issuer)

    12/12/25 5:31:22 PM ET
    $MSGM
    Computer Software: Prepackaged Software
    Technology

    CEO Musk Elon bought $999,959,042 worth of shares (2,568,732 units at $389.28) (SEC Form 4)

    4 - Tesla, Inc. (0001318605) (Issuer)

    9/15/25 6:01:19 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Director Delta John bought $20,426 worth of shares (7,000 units at $2.92) (SEC Form 4)

    4 - Motorsport Games Inc. (0001821175) (Issuer)

    8/21/25 4:05:22 PM ET
    $MSGM
    Computer Software: Prepackaged Software
    Technology

    $AGRX
    $ALLR
    $ATHX
    $BACK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tigress Financial resumed coverage on Tesla with a new price target

    Tigress Financial resumed coverage of Tesla with a rating of Buy and set a new price target of $550.00

    2/12/26 10:13:29 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Analyst reiterated coverage on Tesla with a new price target

    Analyst reiterated coverage of Tesla with a rating of Underweight and set a new price target of $145.00 from $150.00 previously

    1/30/26 8:00:23 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Wells Fargo reiterated coverage on Tesla with a new price target

    Wells Fargo reiterated coverage of Tesla with a rating of Underweight and set a new price target of $130.00 from $120.00 previously

    1/12/26 9:31:17 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    $AGRX
    $ALLR
    $ATHX
    $BACK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

    MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") for gross proceeds of $205 million upon the closing of the transaction. In December 2023, Sentynl Therapeutics, Inc. ("Sentynl") assumed full responsibility for the development and commercialization of ZYCUBO® (copper histidinate, formerly known as CUTX-101) from Cyprium. The PRV was issued upon approval of ZYCUBO by the U.S. Food and Drug Administration ("FDA") on January 12, 2026

    2/23/26 9:24:14 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

    MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") for gross proceeds of $205 million upon the closing of the transaction. In December 2023, Sentynl Therapeutics, Inc. ("Sentynl") assumed full responsibility for the development and commercialization of ZYCUBO® (copper histidinate, formerly known as CUTX-101) from Cyprium. The PRV was issued upon approval of ZYCUBO by the U.S. Food and Drug Administration ("FDA") on January 12, 2026

    2/23/26 8:30:00 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

    ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for rare and neurologic diseases, today announced that it has entered into an exclusive worldwide license agreement with Duke University for patents and know-how pertaining to ATX-04 (clenbuterol), a well-characterized small-molecule β2-adrenergic agonist, in clinical development for the treatment of Pompe disease. Pompe d

    2/23/26 8:00:00 AM ET
    $ATXI
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $ALLR
    $ATHX
    $BACK
    SEC Filings

    View All

    IMAC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - IMAC Holdings, Inc. (0001729944) (Filer)

    2/27/26 4:00:35 PM ET
    $BACK
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Motorsport Games Inc.

    SCHEDULE 13D/A - Motorsport Games Inc. (0001821175) (Subject)

    2/25/26 7:27:40 PM ET
    $MSGM
    Computer Software: Prepackaged Software
    Technology

    Motorsport Games Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Motorsport Games Inc. (0001821175) (Filer)

    2/25/26 5:05:10 PM ET
    $MSGM
    Computer Software: Prepackaged Software
    Technology

    $AGRX
    $ALLR
    $ATHX
    $BACK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wilson-Thompson Kathleen exercised 40,000 shares at a strike of $14.99 and sold $10,692,814 worth of shares (25,731 units at $415.56), increasing direct ownership by 264% to 19,669 units (SEC Form 4)

    4 - Tesla, Inc. (0001318605) (Issuer)

    2/27/26 7:00:21 PM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Large owner Zoi Mike sold $86,951 worth of shares (24,024 units at $3.62) (SEC Form 4)

    4 - Motorsport Games Inc. (0001821175) (Issuer)

    2/27/26 6:23:34 PM ET
    $MSGM
    Computer Software: Prepackaged Software
    Technology

    Large owner Zoi Mike sold $224,334 worth of shares (62,828 units at $3.57) (SEC Form 4)

    4 - Motorsport Games Inc. (0001821175) (Issuer)

    2/25/26 8:52:37 AM ET
    $MSGM
    Computer Software: Prepackaged Software
    Technology

    $AGRX
    $ALLR
    $ATHX
    $BACK
    Leadership Updates

    Live Leadership Updates

    View All

    Scientists Pointing to Hidden Power Source That Could Reshape Future of AI

    This article has been disseminated on behalf of MAX Power Mining Corp. and may include a paid advertisement. AUSTIN, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- MiningNewsWire: Global electricity demand is reaching a pivotal turning point. The International Energy Agency (IEA) now projects that global data-center electricity use will almost double by 2030, with AI-focused facilities increasing their consumption more than four times over the same span — a trajectory pushing power grids in the United States, China, Europe, Southeast Asia and other regions to their limits. The bottleneck is no longer data throughput or semiconductor performance; the critical constraint has become electricity it

    12/3/25 8:30:00 AM ET
    $AMZN
    $AVGO
    $META
    Catalog/Specialty Distribution
    Consumer Discretionary
    Semiconductors
    Technology

    Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

        TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology, today announced the appointment of Jeff Ervin as the Company's new Chief Financial Officer (CFO). He succeeds Alexander Epshinsky, who will remain engaged with the Company during a transition period. Mr. Ervin brings nearly two decades of executive leadership experience across the healthcare, biotech, and other

    7/7/25 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical to Join Russell 2000® and Russell 3000® Indexes

    SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index reconstitution. "We are very pleased to be included in the Russell 2000® and Russell 3000

    6/24/25 8:30:29 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $ALLR
    $ATHX
    $BACK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bluejay Diagnostics Inc.

    SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

    11/14/24 5:49:49 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by TC BioPharm (Holdings) plc

    SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)

    11/14/24 4:41:42 PM ET
    $TCBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bluejay Diagnostics Inc.

    SC 13G/A - Bluejay Diagnostics, Inc. (0001704287) (Subject)

    11/14/24 3:54:54 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    $AGRX
    $ALLR
    $ATHX
    $BACK
    Financials

    Live finance-specific insights

    View All

    UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

    MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") for gross proceeds of $205 million upon the closing of the transaction. In December 2023, Sentynl Therapeutics, Inc. ("Sentynl") assumed full responsibility for the development and commercialization of ZYCUBO® (copper histidinate, formerly known as CUTX-101) from Cyprium. The PRV was issued upon approval of ZYCUBO by the U.S. Food and Drug Administration ("FDA") on January 12, 2026

    2/23/26 9:24:14 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

    MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") for gross proceeds of $205 million upon the closing of the transaction. In December 2023, Sentynl Therapeutics, Inc. ("Sentynl") assumed full responsibility for the development and commercialization of ZYCUBO® (copper histidinate, formerly known as CUTX-101) from Cyprium. The PRV was issued upon approval of ZYCUBO by the U.S. Food and Drug Administration ("FDA") on January 12, 2026

    2/23/26 8:30:00 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Motorsport Games Receives Autosport "Pioneering & Innovation" Award Nomination For Le Mans Ultimate and Reports Strong Player Engagement Growth Following Version 1.2 Update

    MIRAMAR, Fla., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Motorsport Games Inc. (NASDAQ:MSGM) ("Motorsport Games" or "the Company"), a racing game developer, publisher, and esports ecosystem provider of official motorsport series including Le Mans Ultimate, is pleased to share the title's nomination for the Autosport "Pioneering & Innovation" Award. This award nomination recognizes initiatives that advance motorsport through technology, engagement, and innovation and will be presented to the winner in a ceremony on Wednesday 21st January 2026 in London, England. The nomination places Le Mans Ultimate alongside leading projects across the global motorsport industry and underscores the title's stron

    1/20/26 9:00:00 AM ET
    $MSGM
    Computer Software: Prepackaged Software
    Technology